Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 33Burkitt Lymphoma 32Lymphoma 30Leukemia, Myeloid, Acute 29Lymphoma, Non-Hodgkin 28Recurrence 26Breast Neoplasms 26Lymphoma, B-Cell 23Neoplasms 22Myelodysplastic Syndromes 20Lymphoma, Follicular 20Leukemia, Lymphocytic, Chronic, B-Cell 20Hodgkin Disease 17Triple Negative Breast Neoplasms 16Leukemia 16Ovarian Neoplasms 15Hematologic Neoplasms 15Melanoma 14Neuroblastoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Pancreatic Neoplasms 11Leukemia, Biphenotypic, Acute 10Sarcoma 9Neoplasm Metastasis 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myelomonocytic, Chronic 9

Interventions

fludarabine 1aldesleukin 1Zoledronic Acid 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Giant Cell Tumor of Bone × Cyclophosphamide × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡